GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Genetics

Pharmaceutical

Cardiology

GENESIS Pharma

More Like This

PR Newswire associated0

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe

GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia